SABS insider filings
SAB Biotherapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen SABS transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Kropotova Alexandra — CHIEF MEDICAL OFFICER | 1 | — | — | 1 |
Recent insider filings — SAB Biotherapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 473 | EDGAR |
| 2026-06-26 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 988 | EDGAR |
| 2026-03-25 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 988 | EDGAR |
| 2026-02-05 | 4 | Sullivan Eddie Joe — PRESIDENT, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Bausch Christoph Lawrence — CHIEF OPERATING OFFICER | Grant/award (A): 1,800,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | To Lucy — See Remarks | Grant/award (A): 2,400,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Grant/award (A): 2,400,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Reich Samuel J — CEO, Director | Grant/award (A): 4,800,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Jain Rita — Director | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | ZACCARDELLI DAVID — Director | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Polvino William James — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Ellias Helen K. — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Giberson Scott — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Link David — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Lucera Erick — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | SKYLER JAY S — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 988 | EDGAR |
| 2025-10-01 | 4 | Moin Andrew — Director | Option exercise (M): 1,740,000 @ $1.75 · Option exercise (M): 17,400 (derivative) | EDGAR |
| 2025-10-01 | 4 | Sessa Capital (Master), L.P. — Director Sessa Capital GP, LLC — Director Sessa Capital IM, L.P. — Director Sessa Capital IM GP, LLC — Director Petry John — Director | Option exercise (M): 1,740,000 @ $1.75 · Option exercise (M): 17,400 (derivative) | EDGAR |
| 2025-09-22 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 1,977 | EDGAR |
| 2025-08-28 | 4 | To Lucy — See Remarks | Grant/award (A): 1,200,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Bausch Christoph Lawrence — CHIEF OPERATING OFFICER | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Sullivan Eddie Joe — PRESIDENT, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Grant/award (A): 2,400,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Reich Samuel J — CEO & EXECUTIVE CHAIRMAN, Director | Grant/award (A): 4,800,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Moin Andrew — Director | Grant/award (A): 228,500 (derivative) · Grant/award (A): 228,500 (derivative) · Grant/award (A): 114,250 (derivative) | EDGAR |
| 2025-07-24 | 4 | Sessa Capital (Master), L.P. — Director Sessa Capital GP, LLC — Director Sessa Capital IM, L.P. — Director Sessa Capital IM GP, LLC — Director Petry John — Director | Grant/award (A): 228,500 (derivative) · Grant/award (A): 228,500 (derivative) · Grant/award (A): 114,250 (derivative) | EDGAR |
| 2025-04-01 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 1,179 | EDGAR |
| 2024-12-31 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Tax withholding (F): 9,072 | EDGAR |
| 2024-11-05 | 4 | Ellias Helen K. — Director | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-08-13 | 4 | To Lucy — See Remarks | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Link David Charles — Director | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 9,305 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Polvino William James — Director | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 13,958 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Sullivan Eddie Joe — PRESIDENT, Director | Grant/award (A): 46,528 (derivative) @ $0 · Grant/award (A): 4,447 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Giberson Scott — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Lucera Erick — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Spragens Jeffrey G — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | Reich Samuel J — CEO & EXECUTIVE CHAIRMAN, Director | Grant/award (A): 35,700 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | SKYLER JAY S — Director | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | HAMILTON CHRISTINE E — Director | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 5,815 (derivative) @ $0 · Grant/award (A): 4,447 (derivative) @ $0 · Grant/award (A): 44,202 (derivative) @ $0 · Grant/award (A): 2,326 (derivative) @ $0 | EDGAR |
| 2024-02-23 | 4 | Sullivan Eddie Joe — PRESIDENT, Director | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2024-02-23 | 4 | Bausch Christoph Lawrence — CHIEF OPERATING OFFICER | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2024-02-23 | 4 | King Michael — CHIEF FINANCIAL OFFICER | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-02-23 | 4 | Kropotova Alexandra — CHIEF MEDICAL OFFICER | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2024-02-23 | 4 | Reich Samuel J — CEO & EXECUTIVE CHAIRMAN, Director | Grant/award (A): 434,000 (derivative) @ $0 | EDGAR |
| 2023-12-08 | 4 | Sullivan Eddie Joe — Chief Executive Officer, Director | Purchase (P): 1,740 @ $0.88 | EDGAR |
| 2023-11-30 | 4 | King Michael — CHIEF FINANCIAL OFFICER | Purchase (P): 5,000 @ $0.90 | EDGAR |
| 2023-11-30 | 4 | Reich Samuel J — Executive Chairman, Director | Purchase (P): 11,000 @ $0.89 | EDGAR |
| 2023-11-28 | 4 | Ellias Helen K. — Director | Option exercise (M): 2,857,142 · Option exercise (M): 1,800 (derivative) @ $1,000 | EDGAR |
| 2023-11-28 | 4 | Sessa Capital (Master), L.P. — Director Sessa Capital GP, LLC — Director Sessa Capital IM, L.P. — Director Sessa Capital IM GP, LLC — Director Petry John — Director | Option exercise (M): 4,584,571 · Option exercise (M): 31,269 (derivative) @ $1,000 · Option exercise (M): 28,380 (derivative) @ $1,000 | EDGAR |
Recent 8-K events — SAB Biotherapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-29 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SABS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs